Latest News
Manchester, UK, June 13, 2022: Monument Therapeutics, a stratified medicine company, today announced that their first-in-human Phase I study of MT1980, a novel formulation of an on-market anti-inflammatory compound, has commenced. MT1980 has been...
Companies to research Antibody-Drug Conjugates (ADC) to address cancers of high unmet need
Collaboration to utilize ImmunoGen’s ADC linker-payload technology directed to targets identified by OBT
Each company may select a n...
Proveca has entered an exclusive agreement with Mawdsley Brooks Brazil, part of global pharmaceutical services provider Mawdsleys, to commercialise and distribute Sialanar® in Brazil.
Under the terms of the agreement, Mawdsley Brooks Brazil w...
SAFE has been designed to reduce the burden on overstretched clinicians and care home staff by alerting them to pending falls events. A recently published white paper projected that falls amongst older people will increase by 3.9% a year mean...
A pioneering clinical trial of new technology to predict the risk of patients developing Acute Kidney Injury (AKI) has begun at Manchester University NHS Foundation Trust (MFT). The STABILITY UO (Urine Output) clinical risk prediction te...